HSK41959 / Haisco - LARVOL DELTA

Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion (clinicaltrials.gov) - P1 | N=245 | Recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.

New P1 trial • Solid Tumor

HSK41959-2: An oral MTA-cooperative PRMT5 inhibitor for MTAP deleted cancer (AACR 2024) - "Meanwhile in the HCT116 MTAP-WT xenograft model, HSK41959-2 did not show tumor growth inhibition at 100 mpk. In conclusion, HSK41959-2 is a promising oral MTA-cooperative PRMT5 inhibitor, it was nominated as a development candidate."

Oncology • CD34 • MTAP